Fundraising Foxクオリプス株式会社
Osaka, JP · 2 known investors
Find your way into クオリプス株式会社
Sign up to see every warm intro you have to クオリプス株式会社
- Paths you didn't know you had: your email and LinkedIn already hold routes to the クオリプス株式会社 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cuorips develops regenerative medicine products based on human iPS cell technology, including its heart muscle cell sheet "Heart®" (Rehart) for treating severe heart failure caused by ischemic cardiomyopathy, along with catheter-based therapies and compound drugs (YS series). The Japan-based company, spun out of Osaka University research, also builds cell mass-manufacturing infrastructure (VMaCS) and is listed on the Tokyo Stock Exchange Growth market.
Founders & leadership
TK
Takayuki KusanagiRepresentative Director, President & CEO
TT
Tadayuki TanimuraDirector, Executive Vice President
KH
Kazuyoshi HiraoDirector, Executive Vice President & Chief Business Officer
YS
Yoshiki SawaDirector, Chief Medical Science Officer
Investors · 2
Frequently asked questions
- What does クオリプス株式会社 do?
- Cuorips develops regenerative medicine products based on human iPS cell technology, including its heart muscle cell sheet "Heart®" (Rehart) for treating severe heart failure caused by ischemic cardiomyopathy, along with catheter-based therapies and compound drugs (YS series). The Japan-based company, spun out of Osaka University research, also builds cell mass-manufacturing infrastructure (VMaCS) and is listed on the Tokyo Stock Exchange Growth market.
- Who are クオリプス株式会社's investors?
- クオリプス株式会社's investors include Kyoto University Innovation Capital, Nippon Venture Capital.
- Where is クオリプス株式会社 headquartered?
- クオリプス株式会社 is headquartered in Osaka, JP.